In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions

January 3, 2021

The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism

July 21, 2020

New patents for possible tyrosine "harvesting" drug to help eliminate excess tyrosine.

April 14, 2020

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

December 18, 2019

Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients

December 4, 2019

http://ensemblecontrelatyrosinemie.fr/en/

The Tyrosinemia Society and the French sister society "Ensemble contre la tyrosinemie" partner to share experiences and clinical research directions.

Orphan disease treatment “at a tipping point” thanks to advances in clinical pharmacology

Diana LaChance, The University of Alabama in Huntsville

July 3, 2019

Tyrosinemia Society, Inc. Partners with PatientsLikeMe to the Tyrosinemia Community

February 26, 2021